FundingWatcher
Home / Startups / By venture fund / Qiming Venture Partners portfolio companies

Qiming Venture Partners portfolio companies

Updated 16 Nov 2026

http://www.qimingvc.com

Qiming Venture Partners portfolio companies
One-time CSV
  • 154 funded companies, 89 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-investor-qiming-venture-partners.csv154 rows × 18 columns
CompanyCityLast roundAmountDate
Insilico MedicineCambridgeSeries E$123.0M2025-03-13
InfinigenceXuhuiSeries C$343.7M2026-10-12
Shengshu TechnologyBeijingSeries B$292.7M2026-04-10
Insta360ShenzhenSeries E$20.0M2019-09-01
Sanegene BioWoburnSeries B$110.0M2025-12-08
Windward BioBaselSeries B$165.0M2026-05-04
AxeraBeijingSeries C$136.1M2025-04-09
BreezeBioBrisbaneSeries B$60.0M2026-02-25

8 rows of the CSV in 5 of its 18 columns.

154
Startups
$7.6B
Total raised
21
Funded in the last 12 months
$1.6B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 154
30 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Infinigence Infinigence develops AI infrastructure and computing solutions for training and deploying AI models. Artificial intelligence Xuhui, China Series C $343.7M 2026-10-12 $587.5M Qiming Venture Partners, Legend Capital 51 to 100 2023
AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou, China Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
Tianhu Technology Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. Artificial intelligence Minhang, China Series A $29.0M 2026-07-13 $54.2M Qiming Venture Partners, GSR United Capital, 3E Bioventures 11 to 50 2021
Prime Lifescience Prime Lifescience develops a big data platform for life sciences research and analysis. Biotech Hangzhou, China Series A $14.7M 2026-06-30 $44.5M Qiming Venture Partners, Qiji Investment, Ennovation Ventures 11 to 50 2021
LTZ Therapeutics LTZ Therapeutics develops novel immunotherapies for cancer and other diseases with unmet clinical needs. Biotech San Francisco, United States Series B $38.0M 2026-05-06 $125.0M Qiming Venture Partners, Shunwei Capital, K2VC +1 11 to 50 2022
Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel, Switzerland Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
Novamab Novamab researches and develops new nanobodies. Biotech Shanghai, China Series B $43.9M 2026-04-24 $97.8M Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 51 to 100 2017
Shengshu Technology Shengshu Technology develops artificial intelligence systems for generative video and multimodal content creation. Artificial intelligence Beijing, China Series B $292.7M 2026-04-10 $441.5M Qiming Venture Partners, Baidu Ventures, Zhuoyuan Capital +1 101 to 250 2023
CIX Technology CIX Technology develops high-performance intelligent computing solutions. Hardware Shanghai, China Series B $144.7M 2026-03-30 $194.7M Qiming Venture Partners, Shunwei Capital, Lenovo Capital and Incubator Group (LCIG) +2 11 to 50 2021
CSR Biotech CSR Biotech provides cell imaging and data processing services for biological research. Biotech Haidian, China Series B $45.0M 2026-03-10 $45.0M Qiming Venture Partners 51 to 100 2019
Tingsheng Technology Tingsheng Technology develops intracardiac ultrasound (ICE) products. Health care Nanjing, China Series B $13.9M 2026-03-05 $52.8M Qiming Venture Partners, Taiyu Investment, Tao Capital +2 2017
Ruining Bio Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection and wound repair. Health care Jiading, China Series C $14.6M 2026-02-28 $38.8M Qiming Venture Partners, Taiyu Investment, Dingxin Capital +1 2018
BreezeBio BreezeBio is a biotechnology company that develops genetic therapies using non-viral delivery to clinically important tissues. Artificial intelligence Brisbane, United States Series B $60.0M 2026-02-25 $127.7M Sequoia Capital, National Science Foundation, Qiming Venture Partners +1 51 to 100 2016
Chaitin Tech Chaitin Tech provides technology-driven cybersecurity solutions. Cybersecurity Beijing, China Series B $71.9M 2026-01-27 $232.5M Matrix Partners China, ZhenFund, Qiming Venture Partners +1 101 to 250 2014
PRCXI Biotechnology PRCXI Biotechnology provides analytical instruments, bioinformatics, and automation solutions for life sciences. Biotech Suzhou, China Series A $14.0M 2025-12-31 $55.0M Qiming Venture Partners, SAIF Partners 101 to 250 2014
DP Technology DP Technology applies AI to scientific research and industrial R&D challenges worldwide. Artificial intelligence Haidian, China Series C $113.9M 2025-12-24 $253.7M Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 101 to 250 2018
SonoSilicon SonoSilicon researches medical-grade micro-on-chip ultrasound systems and chip design. Health care Hangzhou, China Seed $5.5M 2025-12-11 $5.5M Qiming Venture Partners 11 to 50 2023
Sanegene Bio Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. Biotech Woburn, United States Series B $110.0M 2025-12-08 $240.0M Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 51 to 100 2021
Brise Pharma Brise Pharma provides scientific research and technical services in the pharmaceutical field. Biotech Shanghai, China Series A $28.1M 2025-11-11 $228.3M Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 11 to 50 2021
Mech-Mind Robotics Mech-Mind Robotics makes industrial 3D sensors and AI software for intelligent robots. Artificial intelligence Beijing, China Series D $69.9M 2025-08-26 $341.8M Sequoia Capital, Intel Capital, Qiming Venture Partners 501 to 1,000 2016
Qianshou Qianshou is a dating app that matches users with potential life partners through artificial matchmaking. Artificial intelligence Tianjin, China Series B $30.5M 2025-06-12 $30.5M Qiming Venture Partners 1 to 10 2019
Axera Axera develops artificial intelligence SoCs for computer applications as a semiconductor company. Artificial intelligence Beijing, China Series C $136.1M 2025-04-09 $262.1M Qiming Venture Partners, Legend Star, Glory Ventures +1 251 to 500 2019
Insilico Medicine Insilico Medicine develops an AI platform for drug development targeting cancer and age-related diseases. Artificial intelligence Cambridge, United States Series E $123.0M 2025-03-13 $624.3M Qiming Venture Partners, F-Prime, Warburg Pincus +1 101 to 250 2014
Hope Medicine Hope Medicine develops science-driven biopharmaceutical treatments in clinical development. Health care Nanjing, China Series B $18.5M 2024-09-27 $102.6M Qiming Venture Partners, Sinovation Ventures, Trustbridge Partners +2 1 to 10 2018
Guangjing Energy Guangjing Energy develops perovskite solar cell modules for industrialized mass production and sales. Energy Foshan, China Series A $17.8M 2024-08-22 Qiming Venture Partners, Sinovation Ventures, CICC 11 to 50 2022
DST Car DST Car is an energy vehicle rental service platform based in Shenzhen. Commerce Shenzhen, China Series E $100.0M 2024-07-09 Matrix Partners China, Qiming Venture Partners, CICC +1 501 to 1,000 2015
Alpha Biopharma Alpha Biopharma is a clinical-stage biopharmaceutical company. Biotech Huangpu, China Series B $23.9M 2024-06-22 Qiming Venture Partners, TF Capital, LYZZ Capital 51 to 100 2017
DK MedTech DK MedTech manufactures vascular interventional medical device products. Health care Suzhou, China Series E $24.5M 2024-06-21 $36.2M Qiming Venture Partners, Legend Capital, Oriza Seed Capital (Oriza Yuandian) +1 251 to 500 2015
Yidao Biotechnology Yidao Biotechnology researches and develops vaccines and biomedical products. Biotech Suzhou, China Series D $25.2M 2024-05-09 Qiming Venture Partners, Northern Light Venture Capital 2017
Mach Intelligent Driving Mach Intelligent Driving provides driving solutions built on intelligent sensor function modules. Artificial intelligence Wuhu, China Angel $4.1M 2024-04-24 Qiming Venture Partners 2022

Table 1. Qiming Venture Partners portfolio companies: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 154.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 Infinigence Infinigence develops AI infrastructure and computing solutions for training and deploying AI models. Artificial intelligence Xuhui, China Series C $343.7M 2026-10-12 $587.5M Qiming Venture Partners, Legend Capital 51 to 100 2023
2 Shengshu Technology Shengshu Technology develops artificial intelligence systems for generative video and multimodal content creation. Artificial intelligence Beijing, China Series B $292.7M 2026-04-10 $441.5M Qiming Venture Partners, Baidu Ventures, Zhuoyuan Capital +1 101 to 250 2023
3 Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel, Switzerland Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
4 CIX Technology CIX Technology develops high-performance intelligent computing solutions. Hardware Shanghai, China Series B $144.7M 2026-03-30 $194.7M Qiming Venture Partners, Shunwei Capital, Lenovo Capital and Incubator Group (LCIG) +2 11 to 50 2021
5 AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou, China Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
6 DP Technology DP Technology applies AI to scientific research and industrial R&D challenges worldwide. Artificial intelligence Haidian, China Series C $113.9M 2025-12-24 $253.7M Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 101 to 250 2018
7 Sanegene Bio Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. Biotech Woburn, United States Series B $110.0M 2025-12-08 $240.0M Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 51 to 100 2021
8 Chaitin Tech Chaitin Tech provides technology-driven cybersecurity solutions. Cybersecurity Beijing, China Series B $71.9M 2026-01-27 $232.5M Matrix Partners China, ZhenFund, Qiming Venture Partners +1 101 to 250 2014
9 BreezeBio BreezeBio is a biotechnology company that develops genetic therapies using non-viral delivery to clinically important tissues. Artificial intelligence Brisbane, United States Series B $60.0M 2026-02-25 $127.7M Sequoia Capital, National Science Foundation, Qiming Venture Partners +1 51 to 100 2016
10 CSR Biotech CSR Biotech provides cell imaging and data processing services for biological research. Biotech Haidian, China Series B $45.0M 2026-03-10 $45.0M Qiming Venture Partners 51 to 100 2019

Table 2. Qiming Venture Partners portfolio companies: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 GGV Capital Venture capital firm Menlo Park, United States 12 8%
2 Matrix Partners China Venture capital firm Beijing, China 11 7% 3 Houmo.AI, Chaitin Tech, DP Technology
3 IDG Capital Private equity firm Beijing, China 9 6%
4 Shunwei Capital Venture capital firm Beijing, China 8 5% 2 LTZ Therapeutics, CIX Technology
5 ZhenFund Entrepreneurship program Beijing, China 7 5% 1 Chaitin Tech
6 Source Code Capital Venture capital firm Chaoyang, China 7 5% 1 DP Technology
7 CICC Investment bank Beijing, China 7 5%
8 K2VC Angel group Beijing, China 6 4% 2 LTZ Therapeutics, Sanegene Bio
9 Northern Light Venture Capital Venture capital firm Beijing, China 6 4% 1 Sanegene Bio
10 Legend Capital Venture capital firm Beijing, China 5 3% 2 Infinigence, Chaitin Tech
11 Sequoia Capital Venture capital firm Menlo Park, United States 4 3% 1 BreezeBio
12 DCM Ventures Venture capital firm Menlo Park, United States 4 3%
13 Taiyu Investment Venture capital firm Beijing, China 4 3% 3 Novamab, Tingsheng Technology, Ruining Bio
14 SAIF Partners Private equity firm Hong Kong 4 3% 1 PRCXI Biotechnology
15 SIG China (SIG Asia Investments) Private equity firm Huangpu, China 4 3%

Table 3. Qiming Venture Partners portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Software 101 66% $4.5B
Health care 40 26% $4.0B
Artificial intelligence 36 23% $3.7B
Hardware 30 19% $1.7B
Biotech 24 16% $3.1B
Fintech 18 12% $169.6M
Education 9 6% $3.1M
Commerce 9 6%
Cybersecurity 6 4% $232.5M
Energy 3 2% $54.2M

Table 4. Qiming Venture Partners portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Seed 10 6% $5.5M
Series A 36 23% $10.0M
Series B 59 38% $18.9M
Series C 20 13% $38.0M
Series D+ 29 19% $100.0M

Table 5. Qiming Venture Partners portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
China 123 80%
United States 13 8%
Singapore 7 5%
Hong Kong 2 1%
Switzerland 1 1%
India 1 1%
Indonesia 1 1%
Finland 1 1%
Taiwan 1 1%
Saint Kitts and Nevis 1 1%
South Korea 1 1%
Canada 1 1%

Table 6. Qiming Venture Partners portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Beijing 33 21%
Shanghai 18 12%
Hangzhou 15 10%
Haidian 10 6%
Shenzhen 9 6%
Singapore 7 5%
Suzhou 5 3%
Nanjing 4 3%
San Francisco 4 3%
Boston 3 2%
Minhang 3 2%
Guangzhou 3 2%

Table 7. Qiming Venture Partners portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 1 5%
October 2026 1 5% $343.7M
August 2026 1 5% $120.0M
July 2026 1 5% $29.0M
June 2026 1 5% $14.7M
May 2026 2 10% $203.0M
April 2026 2 10% $336.6M
March 2026 4 19% $203.6M
February 2026 3 14% $74.6M
January 2026 1 5% $71.9M
December 2025 4 19% $243.4M

Table 8. Qiming Venture Partners portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 17 11% $1.4B
2025 14 9% $713.1M
2024 20 13% $425.3M
2023 17 11% $269.5M
2022 18 12% $365.9M
2021 14 9% $1.3B

Table 9. Qiming Venture Partners portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 6 4%
2020 to 2022 25 16%
2015 to 2019 72 47%
2010 to 2014 34 22%
Before 2010 17 11%

Table 10. Qiming Venture Partners portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 11 8%
11 to 50 48 33%
51 to 100 33 23%
101 to 250 23 16%
251 to 500 12 8%
501 to 1,000 11 8%
1,001 to 5,000 6 4%

Table 11. Qiming Venture Partners portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many Qiming Venture Partners portfolio companies are on the list?
154, in the file dated 16 November 2026. 21 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 154 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Qiming Venture Partners portfolio companies: 154 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Portfolio companies by country

Portfolio companies by city

Other venture fund portfolios

Cite: FundingWatcher, 154 startups, 16 November 2026. https://fundingwatcher.com/startups/investor/qiming-venture-partners/